LEXX
Lexaria Bioscience·NASDAQ
--
--(--)
--
--(--)
6.01 / 10
Outperform
Liquidity flow evaluation: 7.4/10 demonstrating robust fund flow characteristics. Optimistic overall, block, Small, Medium, Large, and Extra-large patterns are mitigated by pessimistic no significant trends indicators, pointing to positive flow perspective. Analyst coverage indicates overwhelmingly bullish analyst consensus with strong conviction. Rating distribution: Strong Buy(100.0%) among 1 analysts, supported by 4.62 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-26
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate66.7%
What is the analyst consensus for LEXX?
- LEXX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.01/10 (Outperform).
